Radius is a commercial-stage biopharmaceutical company headquartered in Boston, and it focuses on addressing unmet needs in bone health and neuro-orphan diseases. Its lead product, Tymlos was launched in the U.S. in 2017 for the treatment of postmenopausal osteoporosis patients at a high risk of fracture.
Terms of the deal included $10 per share in cash, plus one nontransferable contingent value right per share, representing the contractual right to receive $1 per share in cash, payable upon Tymlos net sales reaching $300 million during any consecutive 12-month period prior to Dec. 31, 2025.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.